Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwill & IntangiblesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

NewAmsterdam Pharma (NAMS) Operating Leases (2022 - 2025)

NewAmsterdam Pharma's Operating Leases history spans 3 years, with the latest figure at $66000.0 for Q4 2025.

  • For Q4 2025, Operating Leases fell 67.33% year-over-year to $66000.0; the TTM value through Dec 2025 reached $66000.0, down 67.33%, while the annual FY2025 figure was $66000.0, 67.33% down from the prior year.
  • Operating Leases for Q4 2025 was $66000.0 at NewAmsterdam Pharma, down from $85000.0 in the prior quarter.
  • Across five years, Operating Leases topped out at $328000.0 in Q2 2024 and bottomed at $57133.9 in Q4 2022.
  • The 3-year median for Operating Leases is $120000.0 (2025), against an average of $155516.7.
  • The largest YoY upside for Operating Leases was 67.33% in 2025 against a maximum downside of 68.6% in 2025.
  • A 3-year view of Operating Leases shows it stood at $57133.9 in 2022, then soared by 253.56% to $202000.0 in 2024, then plummeted by 67.33% to $66000.0 in 2025.
  • Per Business Quant, the three most recent readings for NAMS's Operating Leases are $66000.0 (Q4 2025), $85000.0 (Q3 2025), and $103000.0 (Q2 2025).